Combination treatment with ixazomib and IFN-α resulted in a significant, and synergistic, increase in apoptotic cell death in both the BRAF V600E mutant (A375) and the BRAF wild-type (WM1366) melanoma tumor cell lines. This evidence concerns the gene IFNA2 and neoplasm.